A detailed history of American Century Companies Inc transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, American Century Companies Inc holds 769,673 shares of VYGR stock, worth $5.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
769,673
Previous 470,229 63.68%
Holding current value
$5.84 Million
Previous $3.97 Million 80.57%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$7.15 - $10.84 $2.14 Million - $3.25 Million
299,444 Added 63.68%
769,673 $7.17 Million
Q4 2023

Feb 13, 2024

BUY
$6.28 - $8.81 $2.95 Million - $4.14 Million
470,229 New
470,229 $3.97 Million
Q3 2023

Nov 13, 2023

BUY
$7.55 - $11.25 $1.61 Million - $2.4 Million
213,465 Added 214.67%
312,905 $2.43 Million
Q2 2023

Aug 14, 2023

BUY
$6.94 - $13.99 $690,113 - $1.39 Million
99,440 New
99,440 $1.14 Million
Q2 2020

Aug 13, 2020

SELL
$8.05 - $14.21 $710,927 - $1.25 Million
-88,314 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$6.8 - $14.66 $3,794 - $8,180
558 Added 0.64%
88,314 $808,000
Q4 2019

Feb 12, 2020

SELL
$12.82 - $16.85 $877,887 - $1.15 Million
-68,478 Reduced 43.83%
87,756 $1.22 Million
Q3 2019

Nov 13, 2019

BUY
$16.31 - $28.29 $409,429 - $710,163
25,103 Added 19.14%
156,234 $2.69 Million
Q2 2019

Aug 14, 2019

SELL
$19.18 - $27.88 $1.16 Million - $1.69 Million
-60,532 Reduced 31.58%
131,131 $3.57 Million
Q1 2019

May 14, 2019

BUY
$8.0 - $19.66 $1.33 Million - $3.28 Million
166,687 Added 667.39%
191,663 $0
Q4 2018

Feb 13, 2019

BUY
$8.59 - $18.05 $214,543 - $450,816
24,976 New
24,976 $235,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $293M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.